US healthtech company Massive Bio expands Asia footprint with South Korea market push

Appoints Intralink to engage hospitals, diagnostic labs & oncologists



Massive Bio appoints Intralink to support its expansion into South Korea's oncology sector.

BOCA RATON, FL, UNITED STATES, September 17, 2026 / EINPresswire.com/ -- US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and build partnerships across the country's oncology sector.

Massive Bio provides an AI-powered platform that connects cancer patients with suitable clinical trials. The company works with global pharmaceutical companies, hospitals and oncologists to identify patients who meet the often highly specific requirements of oncology studies. To date, Massive Bio has matched 200,000 patients with 19,000 clinical trials across 17 markets.

Intralink is an international business development consultancy which specialises in helping companies to secure customers, partners and investors in overseas markets. It operates from 27 locations worldwide including Seoul, Silicon Valley, Boston, London, Paris, Düsseldorf, Poznań, Tokyo, Shanghai, Taipei, Bangkok and New Delhi.

To support Massive Bio's expansion into South Korea, Intralink's Seoul team will build relationships with leading hospitals, diagnostic laboratories and oncologists to drive interest in the company's platform and identify opportunities for collaboration.

It will also seek partnerships that will strengthen Massive Bio's ability to connect patients in

South Korea with appropriate clinical trials, while helping pharmaceutical companies recruit the patients they need.

In addition, Intralink is supporting Massive Bio's engagement with the Korean oncology community through key industry events. For example, in November, Massive Bio will join Intralink at the 2026 AACR-KCA Joint Conference on Precision Medicine in Cancer, to hold discussions with potential partners and explore opportunities for collaboration.

Selin Kurnaz, CEO of Massive Bio, said: “South Korea is an important market in our broader Asian expansion plans because of its strong oncology ecosystem, advanced healthcare infrastructure and clinical research landscape.

“Intralink's Korea expertise and network will play a core role in helping us to understand the market's needs, build meaningful partnerships and expand access to our clinical trials platform.”

About Massive Bio

Massive Bio is an agentic AI and real-world data (RWD) company advancing oncology drug development, commercialization, and access to precision medicine. Powered by RNex (Reticulum Nexus™), its platform combines patient-consented multimodal data and clinical intelligence to identify patients, support trial enrollment, and generate real-world evidence. Massive Bio serves pharmaceutical and biotechnology companies, CROs, providers, and researchers across clinical development, commercial strategy, market access, care navigation, and provider engagement. Founded by Selin Kurnaz, Arturo Loaiza-Bonilla, M.D., and Çağatay Çulcuoğlu, Massive Bio operates in 17 countries and is an OpenAI Select Partner, recipient of the DiMe Seal, founding member of CancerX, and participant in the White House Cancer Moonshot initiative.

For more information, visit massivebio.com.

Mert Turkkan
Massive Bio
mturkkan@massivebio.com
Visit us on social media:
LinkedIn
Bluesky
Instagram
Facebook
YouTube
TikTok
X

This press release can be viewed online at: https://www.einpresswire.com/article/942986027

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.